Drug Type Small molecule drug |
Synonyms BMS-387032, SNS 032 |
Target |
Mechanism CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK7 inhibitors(Cyclin-dependent kinase 7 inhibitors), CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H24N4O2S2 |
InChIKeyOUSFTKFNBAZUKL-UHFFFAOYSA-N |
CAS Registry345627-80-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | - | - | |
Multiple Myeloma | Phase 2 | - | - | |
Solid tumor | Phase 2 | US | - | |
CD19 Expressing Malignancies | Phase 1 | US | 01 Feb 2007 | |
Chronic Lymphocytic Leukemia | Phase 1 | US | 01 Feb 2007 | |
Mantle-Cell Lymphoma | Phase 1 | US | 01 Feb 2007 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Jan 2006 |